The purpose of this study is to evaluate the effectiveness of GW406381 (a COX-2 inhibitor)
in treating the signs and symptoms of dental pain following third molar tooth extraction.
A Pivotal Phase III, Single Center, Randomized, Double-Blind, Placebo-Controlled, Parallel
Group Dose-Ranging Study to Investigate the Efficacy and Safety of Single Oral Doses of
10mg, 25mg, 50mg, and 70mg GW406381 and 550mg Naproxen Sodium in Subjects With Pain
Following Third Molar Tooth Extraction
- Scheduled for outpatient surgical removal of at least two third molar teeth.
- Subjects who do not achieve moderate to severe pain.
- Subjects who do not use acceptable contraception.
- Additional medical criteria will be assessed by the investigator.